All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Carrimycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
Carrimycin is a member of the macrolide family of antibiotics produced from a genetically engineered strain of S. spiramyceticus, using synthetic biology. Carrimycin to be tested for safety and efficacy for the treatment of severe COVID-19 in hospitalized patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Sino Biopharmaceutical
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 07, 2020
Details:
The investment deal comes as Sinovac expands supply deals and trials of its experimental COVID-19 vaccine CoronaVac with more countries following positive results from early to mid-stage clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Ad5-nCoV
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Russia has granted approval for clinical trials to be held for the Chinese COVID-19 vaccine Ad5-Ncov involving 8,000 volunteers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 11, 2020
Details:
Tibet Rhodiola Pharmaceutical plans to conduct early and mid-stage trials of the Sputnik V vaccine in China and final-stage trials overseas, although the trials are yet to be approved by regulators.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Brazil National Health Surveillance Agency Anvisa has suspended a clinical trial of Chinese biopharma firm Sinovac’s Covid-19 vaccine, CoronaVac, owing to a severe adverse event.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inactivated SARS-CoV-2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Vero cell
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Sinopharm's Vero cell is under Phase III randomized, double blind trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 Vaccines in healthy population aged 18 years old and above.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CoronaVac
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Brazil's National Health Surveillance Agency (Anvisa) authorizes resumption of the phase III clinical trial of CoronaVac™, the Inactivated COVID-19 Vaccine, which is sponsored by our partner Butantan Institute.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Ad5-nCoV
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2020
Details:
CanSino has launched the Phase III clinical trial for the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV") in Mexico and has successfully vaccinated the first group of subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: CytoDyn
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 12, 2020
Details:
CytoDyn and Chiral Pharma will work together to register leronlimab (PRO 140) for potential approval from the local Food and Drug Administration to treat patients with COVID-19 in the Philippines.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
